Literature DB >> 2626444

Galanthamine, an acetylcholinesterase inhibitor: a time course of the effects on performance and neurochemical parameters in mice.

J E Sweeney1, P S Puttfarcken, J T Coyle.   

Abstract

The time course of the effects of the long-acting acetylcholinesterase (AChE) inhibitor, galanthamine, on a spatial navigation task and on AChE and acetylcholine (ACh) levels were investigated in mice. Mice received either saline or ibotenic acid injections into the nucleus basalis magnocellularis (nBM). The control and nBM group were than trained to perform a modified Morris swim task and the time to find the hidden platform was recorded. The nBM group took significantly longer to find the platform than the control group in the reversal phase of testing. Galanthamine attenuated the performance deficit in the nBM-lesioned group in a time-dependent manner, with peak performance at four hours after injection of 5.0 mg/kg galanthamine IP. This dose impaired performance of the task in control mice, with the most severe deficits observed at two hours after injections when motor activity was severely reduced. Galanthamine (5.0 mg/kg IP) significantly decreased cortical AChE activity and significantly increased cortical ACh content in control mice in a time-dependent manner. The time courses of the neurochemical effects, however, did not correlate precisely with the behavioral time course. Galanthamine concentrations up to 1 x 10(-5) M did not affect choline acetyltransferase (ChAT) activity, [3H]hemicholinium-3 (HCh-3) binding to the choline carrier, [3H]quinuclidinylbenzilate (QNB) binding to muscarinic receptors, or [3H]acetylcholine binding to nicotinic receptors in cortical homogenates. AChE activity was inhibited by galanthamine in cortical homogenates with an IC50 of 4.1 x 10(-7) M.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2626444     DOI: 10.1016/0091-3057(89)90364-x

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  12 in total

1.  Co-modulation of an allosteric modulator of nicotinic receptor-cholinesterase inhibitor (galantamine) and a 5-HT4 receptor agonist (RS-67333): effect on scopolamine-induced memory deficit in the mouse.

Authors:  Thomas Freret; Véronique Lelong-Boulouard; Pierre Lecouflet; Katia Hamidouche; François Dauphin; Michel Boulouard
Journal:  Psychopharmacology (Berl)       Date:  2017-06-19       Impact factor: 4.530

2.  Increased sensitivity to agonist-induced seizures, straub tail, and hippocampal theta rhythm in knock-in mice carrying hypersensitive alpha 4 nicotinic receptors.

Authors:  Carlos Fonck; Raad Nashmi; Purnima Deshpande; M Imad Damaj; Michael J Marks; Anett Riedel; Johannes Schwarz; Allan C Collins; Cesar Labarca; Henry A Lester
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

Review 3.  Galantamine: a review of its use in Alzheimer's disease.

Authors:  L J Scott; K L Goa
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

Review 4.  Anti-dementia drugs and hippocampal-dependent memory in rodents.

Authors:  Carla M Yuede; Hongxin Dong; John G Csernansky
Journal:  Behav Pharmacol       Date:  2007-09       Impact factor: 2.293

Review 5.  Galanthamine.

Authors:  B Fulton; P Benfield
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

6.  Oral Pretreatment with Galantamine Effectively Mitigates the Acute Toxicity of a Supralethal Dose of Soman in Cynomolgus Monkeys Posttreated with Conventional Antidotes.

Authors:  Malcolm Lane; D'Arice Carter; Joseph D Pescrille; Yasco Aracava; William P Fawcett; G William Basinger; Edna F R Pereira; Edson X Albuquerque
Journal:  J Pharmacol Exp Ther       Date:  2020-08-05       Impact factor: 4.030

Review 7.  Clinical pharmacokinetics of galantamine.

Authors:  Martin R Farlow
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 8.  Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.

Authors:  David G Wilkinson; Paul T Francis; Elias Schwam; Jennifer Payne-Parrish
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

9.  Galantamine facilitates acquisition of a trace-conditioned eyeblink response in healthy, young rabbits.

Authors:  Barbara B Simon; Bryan Knuckley; Donald A Powell
Journal:  Learn Mem       Date:  2004 Jan-Feb       Impact factor: 2.460

10.  Cognitive-enhancing effects of polygalasaponin hydrolysate in aβ(25-35)-induced amnesic mice.

Authors:  Shu Ping Xu; Yan Yan Yang; Dan Xue; Jin Xiu Liu; Xin Min Liu; Tai-Ping Fan; Rui le Pan; Pengtao Li
Journal:  Evid Based Complement Alternat Med       Date:  2011-03-06       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.